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1. Introduction 
Traumatic brain injury (TBI) has long been recognized as a leading cause of mortality and 
permanent neurological disability worldwide and has been described as a silent epidemic of 
modern societies. It is most common amongst young individuals, in their productive years 
of life, thereby causing a significant social and financial burden for them, their families and 
the public health system (Maas et al., 2008). 
The pathophysiology of TBI is complex and multifactorial with several pathways involved 
in the damage of the brain. TBI has been classified into primary and secondary injury. The 
primary injury is the result of the external mechanical force at the moment of trauma 
leading to skull fractures, brain contusions, lacerations, diffuse axonal injuries, vascular 
tearing and intracranial hemorrhages (Maas et al., 2008). The initial impact damages directly 
the neuronal tissue via excitatory amino acids release and massive ionic influx referred to as 
traumatic depolarization (Katayama et al., 1995).  
Secondary neuronal damage is induced immediately after primary injury and is mediated 
through several pathophysiologic mechanisms including raised intracranial pressure, 
disruption of blood brain barrier, brain edema, decreased cerebral blood flow, altered tissue 
perfusion, cerebral hypoxia, ischemia and reperfusion injury (Graham et al., 2000). 
Furthermore, a cascade of molecular, neurochemical, cellular and immune processes 
contribute to secondary damage such as disruption of calcium homeostasis, oxidative stress, 
excitatory mediators release, cytoskeletal and mitochondrial dysfunction, Ab-peptide 
deposition, inflammatory cell infiltration and neuronal cell apoptosis and death (Greve & 
Zink, 2009). Gene expression studies have demonstrated that several genes are implicated in 
the pathophysiology of secondary brain damage (Lei et al., 2009). Secondary cascade of 
events were found to dramatically aggregate primary neuronal damage and given that 
primary injury is unavoidable and irreversible, secondary processes are the targets of 
current therapeutic strategies and trials on neuroprotective agents (Jain, 2008).  
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Extensive research has indicated that cellular and humoral inflammation after TBI play a 
key role in the extent of brain injury and repair processes. The initiation, progression and 
resolution of inflammation in TBI is multifaceted involving leukocyte infiltration, activation 
of resident immune cells and secretion of inflammatory mediators such as pro- and anti-
inflammatory cytokines, chemokines, adhesion molecules, complement factors, reactive 
oxygen species and other factors. Several lines of evidence support a dual role for the 
neuroinflammation either detrimental or beneficial depending on the extent, time and site of 
induction. Elucidation of the inflammatory cascade in the injured brain would offer the 
possibility of novel therapies. 
The present article will focus on the TBI induced neuroinflammation and on the current 
knowledge regarding the involvement of innate and adaptive immune system in the 
inflammation and repair following TBI.  
2. Neuroinflammation  
The normal central nervous system (CNS) limits the entry of immune components and is 
traditionally regarded as an immune privileged organ separated from the peripheral immune 
system by the blood-brain-barrier (BBB). However, this concept of limited immune 
intervention in the CNS has been questioned, since under physiological conditions, resident 
brain cells are capable of immune surveillance and expression of immune mediators within the 
CNS. In addition, T-lymphocytes are known to enter the healthy brain parenchyma to perform 
surveillance in the absence of inflammatory stimulus (Hickey, 1999; Becher et al., 2000). During 
inflammatory brain insults the immune privileged status is compromised with an activation of 
innate immune cells and mobilization of specific adaptive immune responses.  
A growing body of evidence suggests a pivotal role of TBI induced cerebral inflammation, 
including activation of resident cells, migration and recruitment of leukocytes and release of 
inflammatory mediators, in the extent of neuronal injury and repair. Inflammation after TBI 
is believed to be triggered by several factors such as extravasated blood products, tissue 
debris, intracellular components, complement fragments, prostaglandins, reactive oxygen 
and nitrogen species. The BBB is disrupted after TBI resulting in invasion of neutrophils, 
monocytes and lymphocytes from the periphery and activation of microglia and other 
resident cells and thus initiating a potent inflammatory response. A biphasic BBB 
breakdown after TBI has been reported with a first opening occurring immediately after the 
primary impact reaching a maximum permeability within a few hours and then being 
declined. A second-delayed opening as a result of secondary injury cascades was found to 
peak around 3-7 days following TBI and can last from days to years (Baskaya et al., 1997; 
Shlosberg et al., 2010). 
The accumulation of leukocytes into the injured brain area is crucial to the extent of 
inflammation and secondary brain damage. Leukocytes migrate out of blood vessels into the 
injured brain parenchyma via binding to the endothelial selectins P and E and the 
intercellular adhesion molecules (ICAMs). Chemokines from the injured brain tissue 
contribute to the expression of these endothelial molecules in the local vasculature. 
Chemokines are produced by resident cells including microglia, astrocytes and neurons in 
response to local inflammation (Ransohoff, 2002). For instance, the chemokine CXCL8 (IL8) 
interacts with leukocytes, triggering the activation of the integrins LFA-1 and CR3 (Mac-1) 
in the surface of leukocytes. These integrins consequently interact with endothelial ICAM-1 
and ICAM-2 leading to a firm adhesion, conformational changes and extravasation of 
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leukocytes between endothelial cells. Finally, these leukocytes migrate along the 
concentration gradient of chemokines to the site of TBI. Neutrophil accumulation peaks 
within 2 days after TBI whereas monocytes accumulate slightly later (Rhodes, 2011).  
Leukocytes are believed to be important in the initiation and progression of inflammation 
following TBI because they contain and release a significant number of inflammatory 
mediators that injure neurons. Increased leukocyte infiltration has been linked to increased 
brain damage. Leukocytes release pro-inflammatory cytokines, proteases, prostaglandins, 
complement factors, free oxygen and nitrogen species which damage neuronal population and 
brain microvasculature and contribute to the disruption of BBB and formation of vasogenic 
edema (Nguyen et al., 2007). Studies in vitro have shown that mixed cultures of hippocampal 
neurons and neutrophils contributed to increased neuronal loss and excitotoxic damage 
(Dinkel et al., 2004). Also, leukocyte accumulation seemed to mediate the detrimental effects of 
chemokines. It was shown that increased intrathecal levels of CXCL8 were correlated to the 
extent of posttraumatic BBB dysfunction and mortality (Kossmann et al., 1997; Whalen et al., 
2000). However, these effects were attenuated by prior depletion of the circulating leukocytes 
(Bell et al., 1996). Leukocytes also contribute to oxidative damage in the injured brain tissue. 
Free oxygen radicals released by leukocytes induce lipid and protein peroxidation, 
mitochondrial and DNA damage and neuronal apoptosis (Tyurin et al., 2000).   
It has been hypothesized that inhibition of neutrophil function or migration would reduce 
the injury size and improve the functional outcome after TBI. This notion has already been 
proved in experimental models of ischemic brain injury. However, the beneficial role of 
leukocyte inhibition is less convincing in TBI experiments. Studies in animal models and 
humans with severe TBI have shown increased expression of the adhesion molecules 
selectin E and ICAM-1 in the early period following TBI (Carlos et al., 1997; McKeating et al., 
1998; Pleines et al., 1998) indicating that these molecules are important in the neutrophil 
recruitment in the injured brain. Administration of monoclonal antibodies directed against 
the leukocyte adhesion molecules CD11b (aM subunit of integrin CR3) and ICAM-1 resulted 
in decreased neutrophil migration (Carlos et al., 1997; Weaver et al., 2000; Knoblach & 
Faden, 2002) and better clinical recovery (Knoblach & Faden, 2002) after experimental brain 
trauma. However, in the latter study the beneficial effect of anti-ICAM-1 treatment was also 
achieved, although to a lesser extent, with the administration of a nonspecific IgG, 
indicating that part of the effects may be attributed to the general properties of the 
antibodies. Moreover, ICAM-1 gene deficient mice with TBI did not demonstrate evidence 
of improved neurological function, reduced lesion volume or neutrophil accumulation 
compared to wild type control mice (Whalen et al., 1999), suggesting that other adhesion 
molecules may also play a significant role in the recruitment of neutrophils. Inhibition of 
neutrophil infiltration was also tested by blocking chemokine expression. Mice deficient in 
CXC receptor 2 which interacts with chemokines CXCL8, CXCL1 and CXCL2 and mediates 
the neutrophil transmigration across the BBB were reported to demonstrate significant 
attenuation of neutrophil infiltration, reduced tissue damage and neuronal loss, especially in 
the delayed phase post injury (Semple et al., 2010a). In a similar study, deletion of monocyte 
chemokine CCL2 gene resulted in improved neurological function, delayed reduction in 
lesion volume and macrophage accumulation (Semple et al., 2010b). Both the latter studies 
support the notion that late inhibition of leukocyte recruitment in TBI may be beneficial for 
the extent of brain trauma and the clinical outcome. These results were not achieved when 
neutrophil depletion was applied early in the course of TBI (Whalen et al., 1999), indicating 
that leukocyte infiltration in the early phase post injury may mediate some beneficial 
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physiologic processes and only delayed and prolonged leukocyte recruitment may be 
deleterious to the neuronal survival.  
Apart from leukocyte infiltration, the humoral components of neuroinflammation were also 
found to play an important role in the initiation, maintenance and resolution of 
inflammation following TBI. The primary traumatic impact and the ensuing injury triggers 
the release of several cytokines which facilitate the migration of inflammatory cells, the 
activation of resident cells, the expression of vascular endothelial molecules and 
chemokines. Cellular sources of cytokines include leukocytes, lymphocytes, microglia, 
astrocytes, endothelial cells and neurons. Cytokines are induced shortly after primary insult 
and this early increase is mediated by resident brain cells. Cytokines have multiple actions 
and targets, and often overlapping biological effects. Cytokines exert their function either 
through binding to their receptors, which are expressed by both glial and neuronal cells, or 
through diverse pathways such as modulation of neurotransmitter receptor function, 
induction of nitric oxide synthase, secretion of chemokines and proteolytic enzymes (Allan 
& Rothwell, 2001). 
Interleukin-1 (IL-1) is a pro-inflammatory cytokine that has been identified as an important 
mediator of the inflammation following TBI. The IL-1 family has three main members: the pro-
inflammatory cytokines IL-1a and IL-1b, which exert their action by binding to the cell surface 
receptor IL-1RI, and the anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra) (Rothwell 
& Luheshi, 2000). The pro-inflammatory cytokines IL-1a and IL-1b have pleiotropic effects 
which are mediated by binding to the IL-1RI. IL-1 triggers inflammatory reactions, leads to 
recruitment of leukocytes, disruption of BBB and formation of edema, induces other 
interleukins, prostagladins, histamine, thromboxane, chemokines and adhesion molecules and 
exerts multiple effects in neuronal, glial and endothelial cells (Hopkins & Rothwell, 1995; 
Rothwell & Hopkins, 1995). IL-1ra is a naturally occurring competitive and highly selective 
inhibitor of IL-1a and IL-1b which binds to the IL-1RI without initiating signal transduction. 
IL-1ra plays an important role in the regulation of the inflammatory response and the balance 
between proinflammatory and anti-inflammatory cytokines (Arend, 1991; Dinarello, 1991).  
In experimental TBI a rapid induction of IL-1b (mRNA expression and protein levels) was 
observed in the very early period following TBI (Fan et al., 1995; Wang & Shuaib, 2002). 
Similarly, IL-1ra was upregulated in response to head injury but shortly after the induction 
of IL-1b (Gabellec et al., 1999).  Elevated levels of IL-1b were also detected intrathecally in 
patients with head injury (Winter et al., 2002). Moreover, these elevated levels were 
correlated to poorer clinical outcome (Chiaretti et al., 2005; Shiozaki et al., 2005).  The 
proinflammatory cytokines IL-1a and IL-1b are believed to initiate inflammation and to 
contribute to neurodegeneration after various brain insults including TBI, whereas IL-1ra 
seemed to be neuroprotective. In experimental animal models, intracerebral or 
intraventricular administration of exogenous IL-1b markedly exacerbates brain injury (Patel 
et al., 2003). In contrast, administration or overexpression of IL-1ra significantly attenuates 
neuronal damage and inflammation (Toulmond & Rothwell, 1995; Sanderson et al., 1999; 
Tehranian et al., 2002). Apart from acute neuroinflammation, TBI induces long-term and 
persistent inflammation with elevation of IL-1 and other cytokines and increased expression 
of beta-amyloid protein and phosphorylated tau protein. This long-term inflammation may 
be the causative link between TBI and traumatic dementia (Hoshino et al., 1998; Holmin & 
Mathiesen, 1999). These data highlight the important role of IL-1 in the acute and chronic 
neuroinflammation following TBI and the possibility of beneficial effects that may ensue 
after its therapeutic inhibition. However, many studies have underlined the complexity of 
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inflammatory processes, the lack of meaningful effects after blocking a single inflammatory 
mediator and the duality of inflammation which means that inflammation may have either 
detrimental or beneficial effects depending on the site, the time of induction, the 
concentration of mediators and the microenvironment (Morganti-Kossmann et al., 2002). 
This duality was demonstrated for IL-1 which aside from its pro-inflammatory effects also 
seems to participate in tissue repair processes, especially when induced at later stages, via 
stimulation of neurotrophic factors synthesis (Spranger et al., 1990; DeKosky et al., 1994; 
Herx et al., 2000), astrocyte proliferation (Appel et al., 1997) and involvement in synaptic 
plasticity (Fagan & Gage, 1990; Bellinger et al., 1993; Ide et al., 1996). 
IL-6 is another cytokine that has been studied in TBI. IL-6 was found to have also a dual role in 
inflammation with either regulatory, anti-inflammatory or inflammatory effects depending on 
the time course and extent of expression (Allan & Rothwell, 2001; Morganti-Kossmann et al., 
2002). The neurotrophic properties of IL-6 are mediated by inhibition of TNFa synthesis, 
induction of IL-1ra and nerve growth factor and attenuation of oxidative stress (Morganti-
Kossmann et al., 2001). On the contrary, IL-6 promotes inflammatory processes by stimulating 
the production of chemokines and adhesion molecules and the recruitment of leukocytes 
(Romano et al., 1997). Elevated levels of IL-6 were observed in the cerebrospinal fluid (CSF) 
and in the serum of patients with TBI and this increase was correlated with a favorable 
neurological outcome (Singhal et al., 2002; Chiaretti et al., 2008). In contrast, other studies 
demonstrated that IL-6 levels were correlated to the clinical severity of TBI patients (Arand et 
al., 2001; Minambres et al., 2003). Studies in animal models provide evidence for a 
neuroprotective effect of IL-6. IL-6 was found at elevated levels in experimental TBI (Shohami 
et al., 1994). Mice deficient for IL-6 had increased numbers of apoptotic neurons, increased 
oxidative stress and delayed healing of the tissue (Penkowa et al., 2000), whereas the same 
group demonstrated that IL-6 transgenic mice exhibited increased reduction of oxidative stress 
and apoptotic cell death after a cryogenic brain injury (Penkowa et al., 2003). 
Tumor necrosis factor-a (TNFa) is another cytokine with a well-documented role in TBI. 
TNFa mRNA and protein is elevated in the early period after experimental TBI and before 
the infiltration of leukocytes suggesting that the early source of TNFa production are the 
resident cells (Riva-Depaty et al., 1994). Elevated levels were also observed in the clinical 
setting of TBI patients (Goodman et al., 1990; Csuka et al., 1999). TNFa has pro-
inflammatory properties similar to that of IL-1 and exacerbates inflammation and secondary 
brain damage after TBI (Allan & Rothwell, 2001). Early upregulation of neuronal TNFa 
expression after TBI was found to contribute to subsequent neurological dysfunction 
(Knoblach et al., 1999). Inhibition of TNFa by the HU-211 compound (a novel TNFa 
production inhibitor), pentoxyfilline and TNF-binding protein resulted in improved 
neurological outcome after closed head injury (Shohami et al., 1997). However, in a phase III 
clinical trial, administration of the HU-211 compound in patients with TBI failed to show 
improved outcome 6 months after the injury, compared to the placebo group (Maas et al., 
2006). These data indicate that neurodegeneration is mediated through various pathological 
pathways and neuroprotection cannot be achieved by blocking a single mediator as other 
alternative pathways may be activated leading to neuronal loss. Furthermore, as reported 
with IL-1, TNFa also has neuroprotective effects and can enhance recovery processes. In a 
very interesting study, knockout mice for the TNFa gene exhibited milder behavioral 
deficits compared to the wild-type mice during the acute period post-injury. However, in 
the long term period (4 weeks post-injury) knockout mice did not recover as well as the 
wild-type mice, had persistent motor deficits and greater cortical tissue loss (Scherbel et al., 
www.intechopen.com
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
28
1999). These results suggest that the time, concentration and the site of TNFa induction may 
determine the driving of inflammatory processes towards neurodegeneration or 
neuroprotection.  
3. Innate immunity   
Microglia, the brain's resident macrophages, are the main cell type of the innate immune 
system of the brain. Microglia, although debatable, seem to originate from bone marrow 
monocytic cells which invade the CNS during embryonic development (Chan et al., 2007). 
Microglia provide a first line of regional defense in the CNS against various pathological 
insults. They are scattered throughout the CNS although some regional differences in their 
localization have been reported as they are more densely distributed in the gray than in the 
white matter and in structures like hippocampus, basal ganglia and substantia nigra (Block 
et al., 2007).  
While resting, microglia have a highly ramified morphology with symmetrically extended, 
motile processes that form a network, which continuously monitor the local 
microenvironment of the brain parenchyma being the most susceptible sensors of brain 
pathology (Nimmerjahn et al., 2005; Kettenmann et al., 2011). In physiological conditions they 
provide surveillance of the CNS homeostasis and they sense neuronal and astrocytic activity 
and other physiological changes such as pH shifts, ion currents and neurotransmitter release 
(Farber & Kettenmann, 2005). This is achieved by the expression of numerous receptors by the 
microglia establishing a delicate neuron-microglia communication (McCluskey & Lampson, 
2000). In an in vitro study the normal neuronal activity was found to inhibit the effects of 
microglia activators such as interferon-γ  signifying the importance of cell to cell interactions 
(Neumann et al., 1996).  
Various brain insults including bacterial lipopolysaccharide (LPS), cytokines, b-amyloid 
peptide and damaged tissue can result in activation of microglia (Nakamura, 2002). Upon 
activation, the cell size increases and the morphology dramatically changes to an amoeboid 
structure which facilitates the migration of microglial cells towards the lesion site and the 
phagocytosis of cellular debris and toxic substances (Raivich, 2005). In response to noxious 
stimuli microglia also proliferate and migrate to the lesion site. The rapidly chemotactic 
convergence to the site of injury is mediated by ATP, glutamate and other chemotactic agents 
released by the injured cells (Davalos et al., 2005; Liu et al., 2009). At this point the morphology 
of activated microglia cannot be discriminated from that of infiltrating macrophages using 
standard immunohistochemical techniques (Streit et al., 1999; Loane & Byrnes, 2010).  
A significant part in the activation of microglia after inflammatory stimuli is the expression 
of constitutive and inducible surface receptors. Activated microglia express pattern 
recognition receptors, cytokine and chemokine receptors, phagocytic receptors, Fc and 
complement receptors, receptors for glutamate, growth factors and several other molecules 
(Gebicke-Haerter et al., 1996; Cho et al., 2006; Kettenmann et al., 2011). Activated microglia 
also express on their surface MHC class I and II molecules, making them able to present 
antigenic peptides and thus modulating T cell responses (Aloisi, 2001).   
The specific profile of the surface receptors determine the phenotype of microglia and their 
functional properties. In line with macrophages phenotype, activated microglia may be 
neurotoxic (M1) due to the secretion of pro-inflammatory cytokines and reactive oxygen and 
nitrogen species. In contrast, activation of microglia may enable them to maintain and 
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enhance neuronal survival (M2) through the release of anti-inflammatory cytokines and 
neurotrophic factors. However, it is possible that M1 and M2 phenotypes may represent the 
two extremes of a wide spectrum of phenotypes that microglia can have in response to the 
type, intensity, persistence of the stimuli and the microenvironment interactions (Mantovani 
et al., 2004). In fact, microglia have plastic properties and at different stages of the disease 
can acquire diverse phenotypes and functions that can be either detrimental or beneficial.  
The activation process begins when resting microglia detect the noxious stimuli or the sub-
products of tissue damage. Microglia become activated, release inflammatory mediators, 
express surface molecules and remove cellular debris by phagocytosis. Once the toxic factors 
are eliminated and under the influences of the invading immune cells and the normal CNS 
cells activated microglia acquire a neurotrophic phenotype and release anti-inflammatory 
cytokines and neurotrophic factors. After a certain period of time inflammation is resolved 
and the activating microglia return to a resting-surveying state retaining some kind of 
memory of the processes. However, under not fully elucidated conditions, this delicate 
balance between activation-termination and neurotoxic-neurotrophic phenotype can be 
disrupted leading to excessive, uncontrolled or prolonged activation of microglia with 
destructive consequences in neuronal survival. Excessive and dysregulated microglia 
activation were elicited after intense and severe CNS insults. Moreover, insufficient 
recruitment of systemic immune cells to the CNS site of lesion may result in an inability to 
suppress and terminate the microglia activation or to turn them into a neuroprotective 
phenotype (Kempermann & Neumann, 2003; Hanisch & Kettenmann, 2007; Popovich & 
Longbrake, 2008; Rivest, 2009; Schwartz & Shechter, 2010). Thus, dysregulation of the innate 
or adaptive immune system may mediate excessive inflammatory damage following brain 
insults. It is obvious that a better understanding of the interaction mechanisms between 
immune cells may facilitate the introduction of novel therapies.  
Several studies have investigated the microglia function after TBI. The release of various 
mediators in the extracellular space after the injured site alters the expression profile of local 
microglia. In a very interesting imaging study of fluorescent labeled microglia it was shown 
that microglia from the intact brain that are nearby the injured site extend their processes 
which reach the damaged site. There the processes and without cell body movement, 
converge and fuse together to form a spherical area of containment that separate the healthy 
from the injured tissue. In other words fused microglial processes act as a barrier that 
contains the tissue debris. This highly dynamic movement of microglial processes is under 
the chemotactic influence of extracellular ATP (Davalos et al., 2005).   
The time of induction and the duration of microglia activation after TBI were found to be 
different from other brain insults such as cerebral ischemia. Studies in humans with TBI 
have revealed a striking delay of microglial activation and proliferation. Markers of 
microglial activation and proliferation were not detected until 3 days post TBI (Beschorner 
et al., 2000; Engel et al., 2000) whereas the same markers were expressed early in cerebral 
ischemia (Postler et al., 1997). This observation although in line with some findings in 
experimental models (Aihara et al., 1995; Holmin et al., 1997) cannot be fully understood. It 
is possible to reflect different activation cascades of microglia after TBI compared to other 
brain insults. However this window delay of microglial activation after TBI may provide a 
therapeutic opportunity when the target would be the microglial activation.  
Several studies in TBI have also demonstrated that inflammation can persist for long period 
of time after the primary traumatic brain insult. Studies in rodents have revealed reactive 
astrocytosis for over a year following brain injury resulting in chronic progressive neuronal 
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tissue loss (Smith et al., 1997; Holmin & Mathiesen, 1999). In primates, microglia activation 
was found to persist for at least 12 months (Nagamoto-Combs et al., 2007). Post-mortem 
studies in humans have shown persistent elevated microglial activity several years after TBI 
(Gentleman et al., 2004). In addition, a recent PET imaging study in humans using a ligand 
that binds to activated microglia revealed increased microglial activation for up to 17 years 
after TBI (Ramlackhansingh et al., 2011). Persistent microglial activation is believed to 
underline both chronic neuroprotective and destructive processes. The precise mechanisms 
for the persistence of inflammatory processes after TBI are not fully understood. It is 
believed that a severe initial neuronal injury with excessive cytokine signals may lead to 
enhanced activation of microglia that further aggravate brain damage feeding a self-
sustaining and self-propelling prolonged vicious circle of neurotoxicity and progressive 
degeneration (Gao & Hong, 2008). This dysregulated and uncontrolled microglial activation 
may be the key for chronic, long-lived and destructive inflammatory processes. The long-
term microglia activation may also provide insights into a potential causative link between 
head injury and Alzheimer’s disease. 
4. Adaptive immunity  
Adaptive immunity refers to an antigen-specific response either cell-mediated or humoral 
aiming at elimination of pathogenic factors. Adaptive immunity is mediated by B and T 
lymphocytes. In experiment TBI, T cells were found to infiltrate the brain parenchyma in a 
biphasic manner: immediately after the primary impact as a result of disruption of BBB and 
in a delayed phage with increased numbers of T cells which represents an active infiltration 
of specific targeting T-cells (Czigner et al., 2007). In other studies it was shown that T cell 
infiltration in the damaged tissue occurred 3-14 days after CNS trauma and persisted for 6 
months (Kigerl et al., 2006; Beck et al., 2010). In post-mortem human studies CD4+ and CD8+ 
were identified in the injured tissue after spinal cord injury (Fleming et al., 2006).  
It is known that the transformation of naive T cells into effector T cells requires an initial 
antigen presentation in secondary lymphoid organs and a re-activation after re-exposure to 
their antigen. However, the exact mechanics of adaptive immune response after brain injury 
have not been fully elucidated and some aspects remain obscure. It is known that naive T 
cells against CNS antigens are circulating in the periphery. After brain insults the cerebral 
auto-antigens are exposed to the peripheral blood cells. The activation of naive T cells can 
take place in the peripheral lymph nodes as a result of BBB disruption and release of 
cerebral antigens into the bloodstream alone or in conjunction with the brain APCs 
(Lenzlinger et al., 2001; Ling et al., 2003; Karman et al., 2004). After activation, T cells traffic 
to the CNS under the influence of chemokine gradient. Microglia are already activated as a 
result of brain tissue damage and release of inflammatory mediators. Activated microlgia 
release at the site of injury cytokines and chemokines, express various surface molecules 
including complement components and induce the expression of adhesion molecules by the 
endothelial cells. These alterations induce the recruitment of the T cells into the injury site. 
Within the CNS, T cells become re-activated against their antigen which is presented to 
them by local microglia and macrophages.  
As already mentioned MHC expression is almost absent in normal brain parenchyma. 
After brain trauma activated microglia upregulate the expression of MHC class I and class 
II and the expression of adhesion molecules and costimulatory factors. Activated 
microglia can act as antigen-presenting cells to T cells by phagocytosis of the tissue debris, 
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processing of the relevant antigen and its subsequent presentation on class I or class II 
MHC (Ankeny et al., 2006).  
Another hypothesis that has been introduced is that the initial activation of T cells takes 
place within CNS. However, data have shown that the interaction between microglia and T 
cells is incomplete and insufficient to support a full activation and proliferation of T cells. In 
an ex vivo study this interaction resulted in increased T cell apoptosis which may reflect a 
regulatory function of microglia upon T cell responses (Ford et al., 1996). It seems possible 
that activated microglia may influence the function and maintenance of auto-reactive T cells 
in the CNS either directly by presenting the antigen causing re-activation of the T cells or 
indirectly by determining the local inflammatory/anti-inflammatory microenvironment and 
the recruitment of T cells.  
The peripheral activation of T cells against cerebral antigens is supported by a number of 
studies. Several studies have provided evidence for a traveling of the antigen from the CNS 
to the peripheral lymph nodes. Fluorescent substances injected into the CNS of animal 
models were detected in the cervical lymph nodes in a few hours after the injection. In 
addition, intracerebrally infused protein antigen was found to elicit the accumulation of 
antigen-specific CD8+ T cells 3 days after the injection (Ling et al., 2003). Moreover, 
experimental and human studies of CNS trauma have revealed the presence of auto-reactive 
T cells against cerebral antigens. Isolated T cells from an animal model of spinal cord injury 
when injected intravenously into naive recipients were found to induce spinal cord 
neuroinflammation and transient hind limb paralysis and ataxic gait (Popovich et al., 1996). 
Additionally auto-reactive T cells against myelin basic protein were found in increased 
frequencies in patients with spinal cord injury compared to multiple sclerosis patients and 
normal controls (Kil et al., 1999).  
Adaptive immunity may mediate either pathogenic or reparative processes based of the 
inflammatory conditions of the microenvironment during activation of T-cells. It has been 
hypothesized that Th1 immune response may aggravate brain damage by pro-inflammatory 
actions whereas Th2 response may alleviate brain damage by anti-inflammatory and 
neurotrophic effects. In a study of freeze cerebral injury activated T cells were found to 
exacerbate brain damage when transferred to rats 24h before the injury (Fee et al., 2003). In 
contrast, in an very intriguing study in animals with injury in the optic nerve it was shown 
that intraperitoneally injected anti-myelin basic protein specific T cells prevented the 
secondary degeneration of retinal ganglion cells (Moalem et al., 1999). These significant data 
were also replicated in an animal model of spinal cord injury. It was shown that 
autoreactive T cells against myelin basic protein or active immunization with myelin basic 
protein improved the recovery by promoting neuroprotective and regenerative processes 
(Hauben et al., 2000). Furthermore, it was showed that Th2 cells specific for myelin basic 
protein had protective effects on neuronal survival. This neuroprotective effect of the 
antigen-specific T cells was influenced by the extent of non-specific activation of the T cells 
(Wolf et al., 2002). In another study of peripheral facial nerve injury CD4+ T cells were found 
to mediate facial motor neurons survival (Serpe et al., 2003).  
These observations of beneficial effects of autoreactive T cells led to the introduction of the 
term “protective autoimmunity” implying that the recognition of an exposed self antigen by 
T cells can result in protection, repair and maintenance of the functional integrity of a tissue 
rather than the initiation of an autoimmune process. (Schwartz et al., 2003; Schwartz & 
Shechter, 2010). Regulatory T cells (CD4+CD25+Foxp3+) that suppress autoimmune activity 
seem to play a central role in protective autoimmunity. The concept of protective 
www.intechopen.com
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
32
autoimmunity raises some interesting therapeutics options. A vaccination with weak CNS 
specific antigens or a modulation of regulatory T cells activity that enhance protective 
autoimmunity would be a novel approach for neuroprotection and repair after CNS trauma 
(Schwartz et al., 2009).  
In conclusion, neuroinflammation seems to play a key role in the pathophysiology of brain 
damage following TBI. A complex interaction between several components and mediators 
of the innate and adaptive immunity appear to determine the extent of inflammation and its 
nature, either destructive or reparative. A better understanding of these mechanisms that 
are implicated in the initiation, progression and termination of the inflammation and the 
communication between immune cells is required for the development of new and effective 
therapeutic strategies.   
5. References  
Aihara, N., et al. (1995). Altered immunoexpression of microglia and macrophages after 
mild head injury. J Neurotrauma, 12, 1, pp. 53-63. 
Allan, S. M. and Rothwell, N. J. (2001). Cytokines and acute neurodegeneration. Nat Rev 
Neurosci, 2, 10, pp. 734-44. 
Aloisi, F. (2001). Immune function of microglia. Glia, 36, 2, pp. 165-79. 
Ankeny, D. P., et al. (2006). Spinal cord injury triggers systemic autoimmunity: evidence for 
chronic B lymphocyte activation and lupus-like autoantibody synthesis. J 
Neurochem, 99, 4, pp. 1073-87. 
Appel, E., et al. (1997). Regulation of GDNF expression in cultured astrocytes by 
inflammatory stimuli. Neuroreport, 8, 15, pp. 3309-12. 
Arand, M., et al. (2001). Early inflammatory mediator response following isolated traumatic 
brain injury and other major trauma in humans. Langenbecks Arch Surg, 386, 4, pp. 
241-8. 
Arend, W. P. (1991). Interleukin 1 receptor antagonist. A new member of the interleukin 1 
family. J Clin Invest, 88, 5, pp. 1445-51. 
Baskaya, M. K., et al. (1997). The biphasic opening of the blood-brain barrier in the cortex 
and hippocampus after traumatic brain injury in rats. Neurosci Lett, 226, 1, pp. 33-6. 
Becher, B., et al. (2000). Brain-immune connection: immuno-regulatory properties of CNS-
resident cells. Glia, 29, 4, pp. 293-304. 
Beck, K. D., et al. (2010). Quantitative analysis of cellular inflammation after traumatic spinal 
cord injury: evidence for a multiphasic inflammatory response in the acute to 
chronic environment. Brain, 133, Pt 2, pp. 433-47. 
Bell, M. D., et al. (1996). Overriding the brain's intrinsic resistance to leukocyte recruitment 
with intraparenchymal injections of recombinant chemokines. Neuroscience, 74, 1, 
pp. 283-92. 
Bellinger, F. P., et al. (1993). Interleukin 1 beta inhibits synaptic strength and long-term 
potentiation in the rat CA1 hippocampus. Brain Res, 628, 1-2, pp. 227-34. 
Beschorner, R., et al. (2000). Differential regulation of the monocytic calcium-binding 
peptides macrophage-inhibiting factor related protein-8 (MRP8/S100A8) and 
allograft inflammatory factor-1 (AIF-1) following human traumatic brain injury. 
Acta Neuropathol, 100, 6, pp. 627-34. 
Block, M. L., et al. (2007). Microglia-mediated neurotoxicity: uncovering the molecular 
mechanisms. Nat Rev Neurosci, 8, 1, pp. 57-69. 
www.intechopen.com
 
Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity 
 
33 
Carlos, T. M., et al. (1997). Expression of endothelial adhesion molecules and recruitment of 
neutrophils after traumatic brain injury in rats. J Leukoc Biol, 61, 3, pp. 279-85. 
Chan, W. Y., et al. (2007). The origin and cell lineage of microglia: new concepts. Brain Res 
Rev, 53, 2, pp. 344-54. 
Chiaretti, A., et al. (2008). Interleukin-6 and nerve growth factor upregulation correlates 
with improved outcome in children with severe traumatic brain injury. J 
Neurotrauma, 25, 3, pp. 225-34. 
Chiaretti, A., et al. (2005). Interleukin 1beta and interleukin 6 relationship with paediatric 
head trauma severity and outcome. Childs Nerv Syst, 21, 3, pp. 185-93; discussion 
194. 
Cho, B. P., et al. (2006). Pathological dynamics of activated microglia following medial 
forebrain bundle transection. Glia, 53, 1, pp. 92-102. 
Csuka, E., et al. (1999). IL-10 levels in cerebrospinal fluid and serum of patients with severe 
traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain 
barrier function. J Neuroimmunol, 101, 2, pp. 211-21. 
Czigner, A., et al. (2007). Kinetics of the cellular immune response following closed head 
injury. Acta Neurochir (Wien), 149, 3, pp. 281-9. 
Davalos, D., et al. (2005). ATP mediates rapid microglial response to local brain injury in 
vivo. Nat Neurosci, 8, 6, pp. 752-8. 
DeKosky, S. T., et al. (1994). Upregulation of nerve growth factor following cortical trauma. 
Exp Neurol, 130, 2, pp. 173-7. 
Dinarello, C. A. (1991). Interleukin-1 and interleukin-1 antagonism. Blood, 77, 8, pp. 1627-52. 
Dinkel, K., et al. (2004). Neurotoxic effects of polymorphonuclear granulocytes on 
hippocampal primary cultures. Proc Natl Acad Sci U S A, 101, 1, pp. 331-6. 
Engel, S., et al. (2000). Dynamics of microglial activation after human traumatic brain injury 
are revealed by delayed expression of macrophage-related proteins MRP8 and 
MRP14. Acta Neuropathol, 100, 3, pp. 313-22. 
Fagan, A. M. and Gage, F. H. (1990). Cholinergic sprouting in the hippocampus: a proposed 
role for IL-1. Exp Neurol, 110, 1, pp. 105-20. 
Fan, L., et al. (1995). Experimental brain injury induces expression of interleukin-1 beta 
mRNA in the rat brain. Brain Res Mol Brain Res, 30, 1, pp. 125-30. 
Farber, K. and Kettenmann, H. (2005). Physiology of microglial cells. Brain Res Brain Res Rev, 
48, 2, pp. 133-43. 
Fee, D., et al. (2003). Activated/effector CD4+ T cells exacerbate acute damage in the central 
nervous system following traumatic injury. J Neuroimmunol, 136, 1-2, pp. 54-66. 
Fleming, J. C., et al. (2006). The cellular inflammatory response in human spinal cords after 
injury. Brain, 129, Pt 12, pp. 3249-69. 
Ford, A. L., et al. (1996). Microglia induce CD4 T lymphocyte final effector function and 
death. J Exp Med, 184, 5, pp. 1737-45. 
Gabellec, M. M., et al. (1999). Expression of interleukin-1 genes and interleukin-1 receptors 
in the mouse brain after hippocampal injury. Neurosci Res, 33, 4, pp. 251-60. 
Gao, H. M. and Hong, J. S. (2008). Why neurodegenerative diseases are progressive: 




Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
34
Gebicke-Haerter, P. J., et al. (1996). Molecular mechanisms of microglial activation. A. 
Implications for regeneration and neurodegenerative diseases. Neurochem Int, 29, 1, 
pp. 1-12. 
Gentleman, S. M., et al. (2004). Long-term intracerebral inflammatory response after 
traumatic brain injury. Forensic Sci Int, 146, 2-3, pp. 97-104. 
Goodman, J. C., et al. (1990). Elevation of tumor necrosis factor in head injury. J 
Neuroimmunol, 30, 2-3, pp. 213-7. 
Graham, D. I., et al. (2000). Recent advances in neurotrauma. J Neuropathol Exp Neurol, 59, 8, 
pp. 641-51. 
Greve, M. W. and Zink, B. J. (2009). Pathophysiology of traumatic brain injury. Mt Sinai J 
Med, 76, 2, pp. 97-104. 
Hanisch, U. K. and Kettenmann, H. (2007). Microglia: active sensor and versatile effector 
cells in the normal and pathologic brain. Nat Neurosci, 10, 11, pp. 1387-94. 
Hauben, E., et al. (2000). Passive or active immunization with myelin basic protein promotes 
recovery from spinal cord contusion. J Neurosci, 20, 17, pp. 6421-30. 
Herx, L. M., et al. (2000). Central nervous system-initiated inflammation and neurotrophism 
in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J 
Immunol, 165, 4, pp. 2232-9. 
Hickey, W. F. (1999). Leukocyte traffic in the central nervous system: the participants and 
their roles. Semin Immunol, 11, 2, pp. 125-37. 
Holmin, S. and Mathiesen, T. (1999). Long-term intracerebral inflammatory response after 
experimental focal brain injury in rat. Neuroreport, 10, 9, pp. 1889-91. 
Holmin, S., et al. (1997). Delayed cytokine expression in rat brain following experimental 
contusion. J Neurosurg, 86, 3, pp. 493-504. 
Hopkins, S. J. and Rothwell, N. J. (1995). Cytokines and the nervous system. I: Expression 
and recognition. Trends Neurosci, 18, 2, pp. 83-8. 
Hoshino, S., et al. (1998). Emergence of immunoreactivities for phosphorylated tau and 
amyloid-beta protein in chronic stage of fluid percussion injury in rat brain. 
Neuroreport, 9, 8, pp. 1879-83. 
Ide, C. F., et al. (1996). Cellular and molecular correlates to plasticity during recovery from 
injury in the developing mammalian brain. Prog Brain Res, 108, pp. 365-77. 
Jain, K. K. (2008). Neuroprotection in traumatic brain injury. Drug Discov Today, 13, 23-24, 
pp. 1082-9. 
Karman, J., et al. (2004). Initiation of immune responses in brain is promoted by local 
dendritic cells. J Immunol, 173, 4, pp. 2353-61. 
Katayama, Y., et al. (1995). Role of excitatory amino acid-mediated ionic fluxes in traumatic 
brain injury. Brain Pathol, 5, 4, pp. 427-35. 
Kempermann, G. and Neumann, H. (2003). Neuroscience. Microglia: the enemy within? 
Science, 302, 5651, pp. 1689-90. 
Kettenmann, H., et al. (2011). Physiology of microglia. Physiol Rev, 91, 2, pp. 461-553. 
Kigerl, K. A., et al. (2006). Comparative analysis of lesion development and intraspinal 
inflammation in four strains of mice following spinal contusion injury. J Comp 
Neurol, 494, 4, pp. 578-94. 
Kil, K., et al. (1999). T cell responses to myelin basic protein in patients with spinal cord 
injury and multiple sclerosis. J Neuroimmunol, 98, 2, pp. 201-7. 
www.intechopen.com
 
Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity 
 
35 
Knoblach, S. M. and Faden, A. I. (2002). Administration of either anti-intercellular adhesion 
molecule-1 or a nonspecific control antibody improves recovery after traumatic 
brain injury in the rat. J Neurotrauma, 19, 9, pp. 1039-50. 
Knoblach, S. M., et al. (1999). Early neuronal expression of tumor necrosis factor-alpha after 
experimental brain injury contributes to neurological impairment. J Neuroimmunol, 
95, 1-2, pp. 115-25. 
Kossmann, T., et al. (1997). Interleukin-8 released into the cerebrospinal fluid after brain 
injury is associated with blood-brain barrier dysfunction and nerve growth factor 
production. J Cereb Blood Flow Metab, 17, 3, pp. 280-9. 
Lei, P., et al. (2009). Microarray based analysis of microRNA expression in rat cerebral cortex 
after traumatic brain injury. Brain Res, 1284, pp. 191-201. 
Lenzlinger, P. M., et al. (2001). Markers for cell-mediated immune response are elevated in 
cerebrospinal fluid and serum after severe traumatic brain injury in humans. J 
Neurotrauma, 18, 5, pp. 479-89. 
Ling, C., et al. (2003). In situ processing and distribution of intracerebrally injected OVA in 
the CNS. J Neuroimmunol, 141, 1-2, pp. 90-8. 
Liu, G. J., et al. (2009). Glutamate induces directed chemotaxis of microglia. Eur J Neurosci, 
29, 6, pp. 1108-18. 
Loane, D. J. and Byrnes, K. R. (2010). Role of microglia in neurotrauma. Neurotherapeutics, 7, 
4, pp. 366-77. 
Maas, A. I., et al. (2006). Efficacy and safety of dexanabinol in severe traumatic brain injury: 
results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol, 5, 
1, pp. 38-45. 
Maas, A. I., et al. (2008). Moderate and severe traumatic brain injury in adults. Lancet Neurol, 
7, 8, pp. 728-41. 
Mantovani, A., et al. (2004). The chemokine system in diverse forms of macrophage 
activation and polarization. Trends Immunol, 25, 12, pp. 677-86. 
McCluskey, L. P. and Lampson, L. A. (2000). Local neurochemicals and site-specific immune 
regulation in the CNS. J Neuropathol Exp Neurol, 59, 3, pp. 177-87. 
McKeating, E. G., et al. (1998). Leukocyte adhesion molecule profiles and outcome after 
traumatic brain injury. Acta Neurochir Suppl, 71, pp. 200-2. 
Minambres, E., et al. (2003). Correlation between transcranial interleukin-6 gradient and 
outcome in patients with acute brain injury. Crit Care Med, 31, 3, pp. 933-8. 
Moalem, G., et al. (1999). Autoimmune T cells protect neurons from secondary degeneration 
after central nervous system axotomy. Nat Med, 5, 1, pp. 49-55. 
Morganti-Kossmann, M. C., et al. (2001). Role of cerebral inflammation after traumatic brain 
injury: a revisited concept. Shock, 16, 3, pp. 165-77. 
Morganti-Kossmann, M. C., et al. (2002). Inflammatory response in acute traumatic brain 
injury: a double-edged sword. Curr Opin Crit Care, 8, 2, pp. 101-5. 
Nagamoto-Combs, K., et al. (2007). Prolonged microgliosis in the rhesus monkey central 
nervous system after traumatic brain injury. J Neurotrauma, 24, 11, pp. 1719-42. 
Nakamura, Y. (2002). Regulating factors for microglial activation. Biol Pharm Bull, 25, 8, pp. 
945-53. 
Neumann, H., et al. (1996). Neuronal control of MHC class II inducibility in rat astrocytes 
and microglia. Eur J Neurosci, 8, 12, pp. 2582-90. 
www.intechopen.com
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
36
Nguyen, H. X., et al. (2007). Polymorphonuclear leukocytes promote neurotoxicity through 
release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha. J 
Neurochem, 102, 3, pp. 900-12. 
Nimmerjahn, A., et al. (2005). Resting microglial cells are highly dynamic surveillants of 
brain parenchyma in vivo. Science, 308, 5726, pp. 1314-8. 
Patel, H. C., et al. (2003). Interleukin-1 in the brain: mechanisms of action in acute 
neurodegeneration. Ann N Y Acad Sci, 992, pp. 39-47. 
Penkowa, M., et al. (2003). Astrocyte-targeted expression of interleukin-6 protects the central 
nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J 
Neurosci Res, 73, 4, pp. 481-96. 
Penkowa, M., et al. (2000). Impaired inflammatory response and increased oxidative stress 
and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia, 32, 3, 
pp. 271-85. 
Pleines, U. E., et al. (1998). Soluble ICAM-1 in CSF coincides with the extent of cerebral 
damage in patients with severe traumatic brain injury. J Neurotrauma, 15, 6, pp. 399-
409. 
Popovich, P. G. and Longbrake, E. E. (2008). Can the immune system be harnessed to repair 
the CNS? Nat Rev Neurosci, 9, 6, pp. 481-93. 
Popovich, P. G., et al. (1996). Concept of autoimmunity following spinal cord injury: 
possible roles for T lymphocytes in the traumatized central nervous system. J 
Neurosci Res, 45, 4, pp. 349-63. 
Postler, E., et al. (1997). Expression of the S-100 proteins MRP-8 and -14 in ischemic brain 
lesions. Glia, 19, 1, pp. 27-34. 
Raivich, G. (2005). Like cops on the beat: the active role of resting microglia. Trends Neurosci, 
28, 11, pp. 571-3. 
Ramlackhansingh, A. F., et al. (2011). Inflammation after trauma: Microglial activation and 
traumatic brain injury. Ann Neurol. 
Ransohoff, R. M. (2002). The chemokine system in neuroinflammation: an update. J Infect 
Dis, 186 Suppl 2, pp. S152-6. 
Rhodes, J. (2011). Peripheral immune cells in the pathology of traumatic brain injury? Curr 
Opin Crit Care, 17, 2, pp. 122-30. 
Riva-Depaty, I., et al. (1994). Contribution of peripheral macrophages and microglia to the 
cellular reaction after mechanical or neurotoxin-induced lesions of the rat brain. 
Exp Neurol, 128, 1, pp. 77-87. 
Rivest, S. (2009). Regulation of innate immune responses in the brain. Nat Rev Immunol, 9, 6, 
pp. 429-39. 
Romano, M., et al. (1997). Role of IL-6 and its soluble receptor in induction of chemokines 
and leukocyte recruitment. Immunity, 6, 3, pp. 315-25. 
Rothwell, N. J. and Hopkins, S. J. (1995). Cytokines and the nervous system II: Actions and 
mechanisms of action. Trends Neurosci, 18, 3, pp. 130-6. 
Rothwell, N. J. and Luheshi, G. N. (2000). Interleukin 1 in the brain: biology, pathology and 
therapeutic target. Trends Neurosci, 23, 12, pp. 618-25. 
Sanderson, K. L., et al. (1999). Interleukin-1 receptor antagonist attenuates regional neuronal 
cell death and cognitive dysfunction after experimental brain injury. J Cereb Blood 
Flow Metab, 19, 10, pp. 1118-25. 
www.intechopen.com
 
Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity 
 
37 
Scherbel, U., et al. (1999). Differential acute and chronic responses of tumor necrosis factor-
deficient mice to experimental brain injury. Proc Natl Acad Sci U S A, 96, 15, pp. 
8721-6. 
Schwartz, M., et al. (2009). Boosting T-cell immunity as a therapeutic approach for 
neurodegenerative conditions: the role of innate immunity. Neuroscience, 158, 3, pp. 
1133-42. 
Schwartz, M., et al. (2003). Protective autoimmunity against the enemy within: fighting 
glutamate toxicity. Trends Neurosci, 26, 6, pp. 297-302. 
Schwartz, M. and Shechter, R. (2010). Systemic inflammatory cells fight off 
neurodegenerative disease. Nat Rev Neurol, 6, 7, pp. 405-10. 
Semple, B. D., et al. (2010b). Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence 
from severe TBI patients and CCL2-/- mice. J Cereb Blood Flow Metab, 30, 4, pp. 769-
82. 
Semple, B. D., et al. (2010a). Deficiency of the chemokine receptor CXCR2 attenuates 
neutrophil infiltration and cortical damage following closed head injury. Neurobiol 
Dis, 40, 2, pp. 394-403. 
Serpe, C. J., et al. (2003). CD4+ T, but not CD8+ or B, lymphocytes mediate facial 
motoneuron survival after facial nerve transection. Brain Behav Immun, 17, 5, pp. 
393-402. 
Shiozaki, T., et al. (2005). Cerebrospinal fluid concentrations of anti-inflammatory mediators 
in early-phase severe traumatic brain injury. Shock, 23, 5, pp. 406-10. 
Shlosberg, D., et al. (2010). Blood-brain barrier breakdown as a therapeutic target in 
traumatic brain injury. Nat Rev Neurol, 6, 7, pp. 393-403. 
Shohami, E., et al. (1997). Cytokine production in the brain following closed head injury: 
dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective 
neuroprotectant. J Neuroimmunol, 72, 2, pp. 169-77. 
Shohami, E., et al. (1994). Closed head injury triggers early production of TNF alpha and IL-
6 by brain tissue. J Cereb Blood Flow Metab, 14, 4, pp. 615-9. 
Singhal, A., et al. (2002). Association between cerebrospinal fluid interleukin-6 
concentrations and outcome after severe human traumatic brain injury. J 
Neurotrauma, 19, 8, pp. 929-37. 
Smith, D. H., et al. (1997). Progressive atrophy and neuron death for one year following 
brain trauma in the rat. J Neurotrauma, 14, 10, pp. 715-27. 
Spranger, M., et al. (1990). Regulation of Nerve Growth Factor (NGF) Synthesis in the Rat 
Central Nervous System: Comparison between the Effects of Interleukin-1 and 
Various Growth Factors in Astrocyte Cultures and in vivo. Eur J Neurosci, 2, 1, pp. 
69-76. 
Streit, W. J., et al. (1999). Reactive microgliosis. Prog Neurobiol, 57, 6, pp. 563-81. 
Tehranian, R., et al. (2002). Improved recovery and delayed cytokine induction after closed 
head injury in mice with central overexpression of the secreted isoform of the 
interleukin-1 receptor antagonist. J Neurotrauma, 19, 8, pp. 939-51. 
Toulmond, S. and Rothwell, N. J. (1995). Interleukin-1 receptor antagonist inhibits neuronal 
damage caused by fluid percussion injury in the rat. Brain Res, 671, 2, pp. 261-6. 
Tyurin, V. A., et al. (2000). Oxidative stress following traumatic brain injury in rats: 
quantitation of biomarkers and detection of free radical intermediates. J Neurochem, 
75, 5, pp. 2178-89. 
www.intechopen.com
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
38
Wang, C. X. and Shuaib, A. (2002). Involvement of inflammatory cytokines in central 
nervous system injury. Prog Neurobiol, 67, 2, pp. 161-72. 
Weaver, K. D., et al. (2000). Effect of leukocyte-endothelial adhesion antagonism on 
neutrophil migration and neurologic outcome after cortical trauma. J Trauma, 48, 6, 
pp. 1081-90. 
Whalen, M. J., et al. (1999). Effect of traumatic brain injury in mice deficient in intercellular 
adhesion molecule-1: assessment of histopathologic and functional outcome. J 
Neurotrauma, 16, 4, pp. 299-309. 
Whalen, M. J., et al. (1999). Neutrophils do not mediate blood-brain barrier permeability 
early after controlled cortical impact in rats. J Neurotrauma, 16, 7, pp. 583-94. 
Whalen, M. J., et al. (2000). Interleukin-8 is increased in cerebrospinal fluid of children with 
severe head injury. Crit Care Med, 28, 4, pp. 929-34. 
Winter, C. D., et al. (2002). A microdialysis method for the recovery of IL-1beta, IL-6 and 
nerve growth factor from human brain in vivo. J Neurosci Methods, 119, 1, pp. 45-50. 
Wolf, S. A., et al. (2002). Neuroprotection by T-cells depends on their subtype and activation 
state. J Neuroimmunol, 133, 1-2, pp. 72-80. 
www.intechopen.com
Brain Injury - Pathogenesis, Monitoring, Recovery and
Management
Edited by Prof. Amit Agrawal
ISBN 978-953-51-0265-6
Hard cover, 522 pages
Publisher InTech
Published online 23, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The present two volume book "Brain Injury" is distinctive in its presentation and includes a wealth of updated
information on many aspects in the field of brain injury. The Book is devoted to the pathogenesis of brain
injury, concepts in cerebral blood flow and metabolism, investigative approaches and monitoring of brain
injured, different protective mechanisms and recovery and management approach to these individuals,
functional and endocrine aspects of brain injuries, approaches to rehabilitation of brain injured and preventive
aspects of traumatic brain injuries. The collective contribution from experts in brain injury research area would
be successfully conveyed to the readers and readers will find this book to be a valuable guide to further
develop their understanding about brain injury.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Efthimios Dardiotis, Vaios Karanikas, Konstantinos Paterakis, Kostas Fountas and Georgios M. Hadjigeorgiou
(2012). Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity, Brain Injury
- Pathogenesis, Monitoring, Recovery and Management, Prof. Amit Agrawal (Ed.), ISBN: 978-953-51-0265-6,
InTech, Available from: http://www.intechopen.com/books/brain-injury-pathogenesis-monitoring-recovery-and-
management/traumatic-brain-injury-and-inflammation-emerging-role-of-innate-and-adaptive-immunity
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
